Cargando…
Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model
Epithelial to mesenchymal transitions (EMT) is a preparatory process for cancer cells to attain motility and further metastasis to distant sites. Majority of DNA damaging drugs have shown to develop EMT as one of the major mechanisms to attain drug resistance. Here we sought to understand the resist...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565729/ https://www.ncbi.nlm.nih.gov/pubmed/31197132 http://dx.doi.org/10.1038/s41419-019-1690-2 |
_version_ | 1783426708860305408 |
---|---|
author | Chakraborty, Souneek Kumar, Aviral Faheem, Mir Mohd Katoch, Archana Kumar, Anmol Jamwal, Vijay Lakshmi Nayak, Debasis Golani, Aparna Rasool, Reyaz Ur Ahmad, Syed Mudabir Jose, Jedy Kumar, Rakesh Gandhi, Sumit G Dinesh Kumar, Lekha Goswami, Anindya |
author_facet | Chakraborty, Souneek Kumar, Aviral Faheem, Mir Mohd Katoch, Archana Kumar, Anmol Jamwal, Vijay Lakshmi Nayak, Debasis Golani, Aparna Rasool, Reyaz Ur Ahmad, Syed Mudabir Jose, Jedy Kumar, Rakesh Gandhi, Sumit G Dinesh Kumar, Lekha Goswami, Anindya |
author_sort | Chakraborty, Souneek |
collection | PubMed |
description | Epithelial to mesenchymal transitions (EMT) is a preparatory process for cancer cells to attain motility and further metastasis to distant sites. Majority of DNA damaging drugs have shown to develop EMT as one of the major mechanisms to attain drug resistance. Here we sought to understand the resistance/survival instincts of cancer cells during initial phase of drug treatment. We provide a tangible evidence of stimulation of EMT factors in Apc knockout colorectal carcinoma model. Our results implied that CPT-treated Apc knockout cohorts depicted increased pro-invasive and pro-survival factors (Vimentin/p(ser38)Vimentin & NFκB). Moreover, by cell sorting experiment, we have observed the expression of Vimentin in early apoptotic cells (AnnexinV positive) from 36 to 48 h of CPT treatment. We also observed the expression of chimeric Sec-AnnexinV-mvenus protein in migrated cells on transwell membrane recapitulating signatures of early apoptosis. Notably, induction of Vimentin-mediated signaling (by CPT) delayed apoptosis progression in cells conferring survival responses by modulating the promoter activity of NFκB. Furthermore, our results unveiled a novel link between Vimentin and ATM signaling, orchestrated via binding interaction between Vimentin and ATM kinase. Finally, we observed a significant alteration of crypt-villus morphology upon combination of DIM (EMT inhibitor) with CPT nullified the background EMT signals thus improving the efficacy of the DNA damaging agent. Thus, our findings revealed a resistance strategy of cancer cells within a very initial period of drug treatment by activating EMT program, which hinders the cancer cells to achieve later phases of apoptosis thus increasing the chances of early migration. |
format | Online Article Text |
id | pubmed-6565729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-65657292019-06-21 Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model Chakraborty, Souneek Kumar, Aviral Faheem, Mir Mohd Katoch, Archana Kumar, Anmol Jamwal, Vijay Lakshmi Nayak, Debasis Golani, Aparna Rasool, Reyaz Ur Ahmad, Syed Mudabir Jose, Jedy Kumar, Rakesh Gandhi, Sumit G Dinesh Kumar, Lekha Goswami, Anindya Cell Death Dis Article Epithelial to mesenchymal transitions (EMT) is a preparatory process for cancer cells to attain motility and further metastasis to distant sites. Majority of DNA damaging drugs have shown to develop EMT as one of the major mechanisms to attain drug resistance. Here we sought to understand the resistance/survival instincts of cancer cells during initial phase of drug treatment. We provide a tangible evidence of stimulation of EMT factors in Apc knockout colorectal carcinoma model. Our results implied that CPT-treated Apc knockout cohorts depicted increased pro-invasive and pro-survival factors (Vimentin/p(ser38)Vimentin & NFκB). Moreover, by cell sorting experiment, we have observed the expression of Vimentin in early apoptotic cells (AnnexinV positive) from 36 to 48 h of CPT treatment. We also observed the expression of chimeric Sec-AnnexinV-mvenus protein in migrated cells on transwell membrane recapitulating signatures of early apoptosis. Notably, induction of Vimentin-mediated signaling (by CPT) delayed apoptosis progression in cells conferring survival responses by modulating the promoter activity of NFκB. Furthermore, our results unveiled a novel link between Vimentin and ATM signaling, orchestrated via binding interaction between Vimentin and ATM kinase. Finally, we observed a significant alteration of crypt-villus morphology upon combination of DIM (EMT inhibitor) with CPT nullified the background EMT signals thus improving the efficacy of the DNA damaging agent. Thus, our findings revealed a resistance strategy of cancer cells within a very initial period of drug treatment by activating EMT program, which hinders the cancer cells to achieve later phases of apoptosis thus increasing the chances of early migration. Nature Publishing Group UK 2019-06-13 /pmc/articles/PMC6565729/ /pubmed/31197132 http://dx.doi.org/10.1038/s41419-019-1690-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Chakraborty, Souneek Kumar, Aviral Faheem, Mir Mohd Katoch, Archana Kumar, Anmol Jamwal, Vijay Lakshmi Nayak, Debasis Golani, Aparna Rasool, Reyaz Ur Ahmad, Syed Mudabir Jose, Jedy Kumar, Rakesh Gandhi, Sumit G Dinesh Kumar, Lekha Goswami, Anindya Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title | Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title_full | Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title_fullStr | Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title_full_unstemmed | Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title_short | Vimentin activation in early apoptotic cancer cells errands survival pathways during DNA damage inducer CPT treatment in colon carcinoma model |
title_sort | vimentin activation in early apoptotic cancer cells errands survival pathways during dna damage inducer cpt treatment in colon carcinoma model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565729/ https://www.ncbi.nlm.nih.gov/pubmed/31197132 http://dx.doi.org/10.1038/s41419-019-1690-2 |
work_keys_str_mv | AT chakrabortysouneek vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT kumaraviral vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT faheemmirmohd vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT katocharchana vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT kumaranmol vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT jamwalvijaylakshmi vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT nayakdebasis vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT golaniaparna vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT rasoolreyazur vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT ahmadsyedmudabir vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT josejedy vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT kumarrakesh vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT gandhisumitg vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT dineshkumarlekha vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel AT goswamianindya vimentinactivationinearlyapoptoticcancercellserrandssurvivalpathwaysduringdnadamageinducercpttreatmentincoloncarcinomamodel |